Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.25016PMID 20336785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening

  2009cited by this paper
• Triple-Negative Breast Cancer: Risk Factors to Potential Targets

  2008cited by this paper
• Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

  2008influential reference
• Parity and disparity in first course treatment of invasive breast cancer

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• Triple-negative breast cancer: therapeutic options.

  2007cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007influential reference
• Comment to Anderson WF, Jatoi I, Devesa SS: Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link Between Etiology and Outcome. Breast Cancer Res Treat 90:127–137, 2005

  2006cited by this paper
• Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

  2006influential reference
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Advances in adjuvant therapy for breast cancer.

  2006cited by this paper
• Breast cancer in African-American women: differences in tumor biology from European-American women.

  2006cited by this paper
• Missed opportunities: racial disparities in adjuvant breast cancer treatment.

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

  2006cited by this paper
• Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy

  2006cited by this paper
• High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

  2005cited by this paper
• Ethnicity and breast cancer: factors influencing differences in incidence and outcome.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome

  2005cited by this paper
• Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma

  2004cited by this paper
• Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.

  2004cited by this paper
• Racial differences in diagnosis, treatment, and clinical delays in a population‐based study of patients with newly diagnosed breast carcinoma

  2004cited by this paper
• Molecular profiling of breast cancer: clinical implications

  2004cited by this paper
• Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures--the public health disparities geocoding project.

  2003cited by this paper
• Differences in breast cancer stage, treatment, and survival by race and ethnicity.

  2003cited by this paper
• Current Perspectives on HER2 Testing: A Review of National Testing Guidelines

  2003cited by this paper
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Meeting highlights: International Consensus Panel on the treatment of primary breast cancer.

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Cancer: The molecular outlook

  2002cited by this paper
• Understanding the utility of adjuvant systemic therapy for primary breast cancer.

  2001cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

  2001cited by this paper
• 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups

  2001cited by this paper
• The Census

  1939cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Guideline-concordance along the cancer care continuum and breast cancer mortality by race and ethnicity: a SEER-Medicare study

  2026cites this paper
• Impact of Ethnic Differences and HER2 Protein Expression on the Age at Breast Cancer Diagnosis: A Mixed Methods Study

  2026cites this paper
• Identifying hormone receptor-positive breast cancer subtypes with recurrence scores derived from pathological data without Ki-67 indices: a clinicopathological study of breast cancer survival in West Asia.

  2026cites this paper
• Understanding the role of neighborhood deprivation in racial disparities in triple‐negative breast cancer

  2025cites this paper
• Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial

  2025cites this paper
• Education level and risk of breast cancer by tumor subtype in the EPIC cohort

  2025cites this paper
• Differences in the distribution of HER2-positive breast tumors according to ethnicity and genetic variants in ERBB2: a special focus on Asian and Latina women

  2025cites this paper
• Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers

  2024cites this paper
• HER2-low prevalence among Hispanic/Latino women with breast cancer: A systematic review and meta-analysis

  2024influential citation
• Genetic Ancestry of 1127 Brazilian Breast Cancer Patients and Its Correlation With Molecular Subtype and Geographic Region.

  2023cites this paper
• Synthetic Reader-Actuators Targeted to Polycomb-Silenced Genes Block Triple-Negative Breast Cancer Proliferation and Invasion

  2023cites this paper
• PIC recruitment by synthetic reader-actuators to polycomb-silenced genes blocks triple-negative breast cancer invasion

  2023cites this paper
• Sociodemographic disparities in molecular testing for breast cancer

  2022cites this paper
• Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer

  2022cites this paper
• Differences in Breast Cancer Presentation at Time of Diagnosis for Black and White Women in High Resource Settings

  2021cites this paper
• Individual‐ and neighborhood‐level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California

  2021cites this paper
• Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis

  2020cites this paper
• Nomograms for prediction of overall and cancer-specific survival in young breast cancer

  2020cites this paper
• Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

  2020cites this paper
• Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database

  2020cites this paper
• Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines

  2020influential citation
• A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth

  2020cites this paper
• Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

  2020cites this paper
• Ethnicity-Related Survival Analysis of Patients with Triple-Negative Breast Cancer

  2019cites this paper
• Estrone Sulfatase Inhibitors as New Anticancer Agents

  2019cites this paper
• Regulation and New Treatment Strategies in Breast Cancer.

  2019cites this paper
• Development of transplantable mouse models to assess the role of prolactin inducible protein in breast tumorigenesis

  2019cites this paper
• Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer

  2019cites this paper
• Therapeutic potential of estradiol in treating breast cancer

  2019cites this paper
• Investigation of the effect of estradiol and subculturing on the receptor expression within hormone-dependent breast cancer cells

  2019cites this paper
• NVP-BEZ235/Chlorin-e6 co-loaded nanoparticles ablate breast cancer by biochemical and photodynamic synergistic effects

  2018cites this paper
• Influence of provider factors and race on uptake of breast cancer gene expression profiling

  2018cites this paper
• Oncological safety of nipple-sparing mastectomy in young patients with breast cancer compared with conventional mastectomy

  2018cites this paper
• Descriptive study of triple negative breast cancer in Eastern Algeria

  2018cites this paper
• Development and Validation of Nomograms for Predicting Overall and Breast Cancer–Specific Survival in Young Women with Breast Cancer: A Population-Based Study

  2018cites this paper
• Breast Cancer Subtypes among Iraqi Patients: Identified by Their ER PR and HER2 Status

  2017cites this paper
• Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee

  2017cites this paper
• Erratum to: Detecting gene signature activation in breast cancer in an absolute, single-patient manner

  2017cites this paper
• Polyphenols as Promising Drugs against Main Breast Cancer Signatures

  2017cites this paper
• Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.

  2017cites this paper
• Geospatial Analysis of Inflammatory Breast Cancer and Associated Community Characteristics in the United States

  2017cites this paper
• Influence of clinical, societal, and treatment variables on racial differences in ER−/PR− breast cancer survival

  2017cites this paper
• Detecting gene signature activation in breast cancer in an absolute, single-patient manner

  2017cites this paper
• Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status of breast cancers in women visiting the Jos University Teaching Hospital

  2017cites this paper
• Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells.

  2016cites this paper
• Long-term outcome in young women with breast cancer: a population-based study

  2016cites this paper
• Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis

  2016cites this paper
• The Meaning of Survivorship as Defined by African American Breast Cancer Survivors

  2016cites this paper
• Prevalence and type of anaemia in receptor negative breast cancer

  2016cites this paper
• Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities.

  2016cites this paper
• Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer

  2016cites this paper
• Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

  2016cites this paper
• Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain

  2016cites this paper
• Breast cancer survival among young women: a review of the role of modifiable lifestyle factors

  2016cites this paper
• Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

  2016cites this paper
• Triple Negative Breast Cancer: Nanosolutions for a Big Challenge

  2015cites this paper
• Epigenetics in breast and prostate cancer.

  2015cites this paper
• CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

  2015cites this paper
• Determinants and Disparities of Survival in Triple-Negative Breast Cancer Patients: A Population-Based Retrospective Longitudinal Cohort Design Utilizing the Cox Proportional Hazard Analytical Model

  2015cites this paper
• Therapeutic and chemopreventive potential of luteolin against growth and metastasis of breast cancer

  2015cites this paper
• EFFECT OF AGE ON PROGNOSIS IN DIFFERENT MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA

  2015cites this paper
• Expression of p53 Protein Product in Triple Negative Breast Cancers and Relation with Clinical and Histopathological Parameters/ Експресија На Р53 Протеинскиот Продукт Кај Тројно Негативните Карциноми На Дојка Во Сооднос Со Клиничките И Хистопатолошките Параметри

  2015cites this paper
• Pancreatic Cancer Disparities in African Americans

  2015cites this paper
• Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

  2015cites this paper
• Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study.

  2015cites this paper
• IDENTIFICATION OF CLEAVAGE REGULATORY MECHANISMS AND PHENOTYPIC CONSEQUENCES TO TARGETING OF THE ADAM 17/ EGFR AXIS IN TRIPLE NEGATIVE BREAST CANCER (TNBC) IN-VITRO

  2015cites this paper
• Socioeconomic status and incidence of breast cancer by hormone receptor subtype

  2015cites this paper
• Design and synthesis of silicon-containing steroid sulfatase inhibitors possessing pro-estrogen antagonistic character.

  2014cites this paper
• In Situ Hybridization Analysis of Invasive Breast Carcinomas with Immunohistochemically Negative Her-2 Status (A National Multicenter Study)

  2014cites this paper
• Features of breast cancer in developing countries, examples from North-Africa.

  2014cites this paper
• [Breast cancer in México: a 10-year trend analysis on incidence and age at diagnosis].

  2014cites this paper
• Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?

  2014cites this paper
• In Situ Hybridization Analysis of Invasive Breast Carcinomas with Immunohistochemically Negative Her-2 Status (A National Multicenter Study) Her-2 Durumu İmmünohistokimya ile Negatif olan İnvaziv Meme Karsinomlarinda İn Situ Hibridizasyon Yöntemi ile Değerlendirme (Ulusal Çok Merkezli Çalişma)

  2014cites this paper
• Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

  2014cites this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2014cites this paper
• Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011)

  2014cites this paper
• Race/Ethnicity and Disparities in Mastectomy Practice in the Breast Cancer Care in Chicago Study

  2014cites this paper
• The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

  2014cites this paper
• Differential Network Analysis Applied to Preoperative Breast Cancer Chemotherapy Response

  2013cites this paper
• Androgen receptor in triple negative breast cancer.

  2013cites this paper
• Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN

  2013cites this paper
• Epidemiology and prognosis of breast cancer in young women.

  2013cites this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cites this paper
• Differences in breast cancer hormone receptor status in ethnic groups: a London population.

  2013cites this paper
• How useful are molecular assays in breast cancer in the elderly

  2013cites this paper
• Concomitant Boost Versus Sequential Boost in Breast Conservative Therapy for Early Stage Breast Cancer

  2013cites this paper
• Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival

  2012cites this paper
• Race and the Prognostic Influence of p53 in Women with Breast Cancer

  2012cites this paper
• Familial breast cancer registry program in patients referred to the cancer institute of Iran.

  2012cites this paper
• Incidence and risk factors for breast cancer subtypes in three distinct South‐East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia

  2012cites this paper
• Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.

  2012cites this paper
• A population-based study of Kurdish breast cancer in northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data

  2012influential citation
• A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications

  2012cites this paper
• Changes in survival by ethnicity of patients with cancer between 1992-1996 and 2002-2006: is the discrepancy decreasing?

  2012cites this paper
• PHYSICAL ACTIVITY ACROSS THE LIFE COURSE AND RISK OF PRE- AND POST-MENOPAUSAL BREAST CANCER

  2012cites this paper
• Finding regions of aberrant DNA copy number associated with tumor phenotype

  2012cites this paper
• Looking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias.

  2012cites this paper
• 21‐Gene recurrence scores

  2012cites this paper
• Breast cancer in young women

  2012cites this paper
• A population-based study of Kurdish breast cancer in northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data

  2012cites this paper